Durvalumab after sequential chemoradiotherapy in stage III, unresectable NSCLC: the phase 2 PACIFIC-6 trial

On the basis of the findings of the phase 3 PACIFIC trial (NCT02125461), durvalumab is standard of care for patients with stage III, unresectable NSCLC and no disease progression after concurrent chemoradiotherapy (cCRT). Many patients are considered unsuitable for cCRT owing to concerns with tolera...

Full description

Bibliographic Details

Main Authors:	Garassino, Marina (Author) , Mazieres, Julien (Author) , Reck, Martin (Author) , Chouaid, Christos (Author) , Bischoff, Helge (Author) , Reinmuth, Niels (Author) , Cove-Smith, Laura (Author) , Mansy, Talal (Author) , Cortinovis, Diego (Author) , Migliorino, Maria R. (Author) , Delmonte, Angelo (Author) , Sánchez, José Garcia (Author) , Chara Velarde, Luis Enrique (Author) , Bernabe, Reyes (Author) , Paz-Ares, Luis (Author) , Perez, Ignacio Diaz (Author) , Trunova, Nataliya (Author) , Foroutanpour, Kayhan (Author) , Faivre-Finn, Corinne (Author)
Format:	Article (Journal)
Language:	English
Published:	9 August 2022
In:	Journal of thoracic oncology Year: 2022, Volume: 17, Issue: 12, Pages: 1415-1427
ISSN:	1556-1380
DOI:	10.1016/j.jtho.2022.07.1148
Online Access:	Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.jtho.2022.07.1148 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1556086422015003
Author Notes:	Marina C. Garassino, MD, Julien Mazieres, MD, Martin Reck, MD, Christos Chouaid, MD, Helge Bischoff, MD, Niels Reinmuth, MD, Laura Cove-Smith, MBChB, Talal Mansy, MBBS, Diego Cortinovis, MD, Maria R. Migliorino, MD, Angelo Delmonte, MD, José Garcia Sánchez, MD, Luis Enrique Chara Velarde, MD, Reyes Bernabe, MD, Luis Paz-Ares, MD, Ignacio Diaz Perez, MD, Nataliya Trunova, MD, Kayhan Foroutanpour, PhD, Corinne Faivre-Finn, MD